World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)

 
Online Download $3,800
Global Site License $7,600
Departmental Site License (one location, up to 10 users) $5,250
Published Feb 1, 2012 | 220 Pages | Pub ID: KLI6772957

This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment:
  • Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
  • Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
  • Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)

The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.

A novel approach in this report is that it provides revenue by product type but also the 'market' for treatments by type of infection, enabling marketers to research the best markets where a variety of products may be implemented.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.

The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers' ability to successfully operate in the market. The issues and trends affecting this market include:

  • Drug Resistance
  • HIV Trends, Cost, and Access to Drug Therapy
  • Other Immunocompromised Population Issues
  • Alliances and Partnerships
  • New Developments
  • Rx-to-OTC Switches
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2011. Historical data was provided for the years 2007 through 2010, with forecast data provided for 2012 through 2015. Compound annual growth rates (CAGRs) are provided for the 2007-2011, 2011-2015 and 2007-2015 periods for each industry segment covered. Competitive analysis is provided for the years 2007 through 2011 with a special focus on 2011. The forecasted market analysis for 2011-2015 was based on probability of approval and sales of products in late stage development, future trends in current product demand, generic penetration, product marketing, and relevant demographic trends.

Companies profiled in this report include:

  • Abbott Laboratories
  • Astellas
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Cubist
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
CHAPTER ONE: EXECUTIVE SUMMARY
  • Introduction
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
  • Overview
    • Introduction to Pathogens
  • Demographics of the World
    • Life Expectancy
  • Infections and Drug Resistance
    • Causes of Drug Resistance
    • Drug Resistance in Select Populations
    • Measures for Reducing Resistance
  • HIV Trends
  • Manufacturer and Marketer Trends
    • Trends in Partnerships and Alliances
    • Developers Trends
    • Aradigm
    • ARD-3100
    • Phase II
    • Cystic fibrosis
    • ARD-3150
    • Phase II
    • Bronchiectasis
    • ARD-1100
    • Preclinical
    • Inhalation anthrax
    • Trends in Rx-to-OTC Switches
CHAPTER THREE: ANTIFUNGAL DRUGS
  • Overview
  • Types of Fungal Infections
    • Superficial
    • Systemic
    • General Fungal Infection Statistics
    • Fungal Infection Risk
  • Description of Antifungal Products
    • Systemic Antifungals
    • Topical Antifungals
  • Market Overview
  • Total Market Size and Forecast
    • Antifungal Market by Product Type
    • Antifungal Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
    • Leading Products
CHAPTER FOUR: ANTIBACTERIAL DRUGS
  • Overview
    • Classification of Antibacterial Organisms
    • Antimicrobial Spectrum
    • Bacterial Resistance
    • Principles of Anti-bacterial Therapy
    • Combination Therapy and Prophylactic Use
    • Bacterial Infection Statistics
    • Bacterial Infection Risk
  • Classifications of Antibacterial Products
    • Aminoglycosides
    • Carbapenems
    • Cephalosporins
    • Macrolides
    • Penicillins
    • Quinolones
    • Sulfonamides
    • Tetracyclines
  • Market Overview
  • Total Market Size and Forecast
    • Antibacterial Market by Product Type
    • Antibacterial Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
  • Leading Products
CHAPTER FIVE: ANTIVIRAL DRUGS
  • Overview: Introduction to Viruses
  • Examples of Pathogenic Viruses
  • Virus Function and Life History
    • Replication in DNA Viruses
    • Replication of RNA Viruses
    • Replication in Retroviruses
  • Host Defenses Against Viruses 8
  • Viral Ploys to Invade Host Cells and Circumvent Host Responses
    • Invasion of Host Cells
    • Subversion of the Immune Response
    • Avoidance of Immune Detection and Attack by Killer Cells
  • HIV and AIDS
  • Viral Infection Statistics
  • Description of Antivirals Products
  • Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
  • Protease Inhibitors
  • Other Antivirals
  • Market Overview
  • Total Market Size and Forecast
    • Antiviral Market by Product Type
    • Antiviral Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
    • Leading Products
CHAPTER SIX: MARKET SUMMARY
  • Market by Product Segment (Antifungals, Antibacterials, Antivirals)
CHAPTER SEVEN: CORPORATE PROFILES
  • Introduction
  • Abbott Laboratories
  • Astellas
  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
  • Bristol-Myers Squibb
  • Cubist
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • APPENDIX: COMPANY DIRECTORY

    TABLE OF EXHIBITS

    CHAPTER ONE: EXECUTIVE SUMMARY

    • Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

    • Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011

    • Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading Suppliers, 2011

    CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

    • Table 2-1: World Population by Selected Geographical Region, 2010 - 2050

    • Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009

    • Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009

    • Table 2-3: Worldwide HIV/AIDS Infections

    • Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number

    • Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, 2009 based on 2010 WHO Guidelines

    • Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines

    • Table 2-7: Anti-Infective Drugs in Development by Developer

    • Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status

    • Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

    CHAPTER THREE: ANTIFUNGAL DRUGS

    • Table 3-1: Incidence of Infections by Type, 2010

    • Figure 3-1: Incidence of Infections by Type, 2010

    • Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

    • Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

    • Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)

    • Table 3-4: The World Market for Antifungal Drugs 2007-2015

    • Figure 3-3: The World Market for Antifungal Drugs 2007-2015

    • Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

    • Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

    • Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

    • Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2007-2015

    • Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2007-2015

    • Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

    • Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

    • Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

    • Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison 2007-2011

    • Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2011

    • Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

    • Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

    CHAPTER FOUR: ANTIBACTERIAL DRUGS

    • Table 4-1: Antibiotics with Difficult Penetration

    • Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010

    • Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections

    • Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

    • Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

    • Table 4-4: Treatment Options for Bacterial Infections , (Type, Brand, and Manufacturer)

    • Table 4-5: The World Market for Antibacterial Drugs 2007-2015

    • Figure 4-3: The World Market for Antibacterial Drugs 2007-2015

    • Table 4-6: Antibacterial Drug Market by Type 2007-2015

    • Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

    • Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

    • Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2007-2015

    • Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2007-2015

    • Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

    • Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

    • Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

    • Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2007-2011

    • Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011

    • Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products 2007-2011

    CHAPTER FIVE: ANTIVIRAL DRUGS

    • Table 5-1: Host Cell Receptors

    • Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010

    • Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections

    • Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)

    • Table 5-4: The World Market for Antiviral Drugs 2007-2015

    • Figure 5-2: The World Market for Antiviral Drugs 2007-2015

    • Table 5-5: Antiviral Drug Market by Type (HIV, Hepatitis and Other Infections) 2007-2015

    • Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015

    • Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015

    • Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2007-2015

    • Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2007-2015

    • Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total)

    • Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)

    • Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009

    • Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2007-2011

    • Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2011

    • Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

    • Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

    CHAPTER SIX: MARKET SUMMARY

    • Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

    • Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015

    • Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011

    • Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015

  • In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

    We were unable to search inside this report.

    Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

    Please note that your term must be at least three characters long and numbers will be blocked by the # sign.